acquisition
-
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
For more bio-news, please follow DrugTimes. Many thanks!
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
